KDR and hepatocellular carcinoma: Currently sorafenib, a VEGFR inhibitor which also counters the activity of platelet-derived growth factor receptor β (PDGFR-β), the cytokine receptor c-KIT, Raf-1 and B-Raf, is the first line treatment that was approved by the U.S. Food and Drug Administration (FDA) for the advanced-stage HCC patients [3, 4].